Compare · KZIA vs PCVX
KZIA vs PCVX
Side-by-side comparison of Kazia Therapeutics Limited (KZIA) and Vaxcyte Inc. (PCVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. KZIA focuses on Biotechnology: Pharmaceutical Preparations, while PCVX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- PCVX is the larger of the two at $10.03B, about 97.5x KZIA ($102.9M).
- PCVX has been more active in the news (8 items in the past 4 weeks vs 7 for KZIA).
- PCVX has more recent analyst coverage (11 ratings vs 9 for KZIA).
- Company
- Kazia Therapeutics Limited
- Vaxcyte Inc.
- Price
- -
- -
- Market cap
- $102.9M
- $10.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 8
- Recent ratings
- 9
- 11
Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Vaxcyte Inc.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
Latest KZIA
- Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
- SEC Form NT 20-F filed by Kazia Therapeutics Limited
- Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
- Needham initiated coverage on Kazia Therapeutics with a new price target
- Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
- Guggenheim initiated coverage on Kazia Therapeutics with a new price target
- Leerink Partners initiated coverage on Kazia Therapeutics with a new price target
- SEC Form 424B3 filed by Kazia Therapeutics Limited
- SEC Form 424B3 filed by Kazia Therapeutics Limited
- SEC Form 424B3 filed by Kazia Therapeutics Limited
Latest PCVX
- Chief Technical Ops Officer Dhaliwal Harpreet S. exercised 17,000 shares at a strike of $24.79 and sold $1,153,103 worth of shares (17,000 units at $67.83) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.
- SVP, Finance & CAO Cowan Elvia exercised 3,000 shares at a strike of $25.92 and sold $182,753 worth of shares (3,000 units at $60.92) as part of a pre-agreed trading plan (SEC Form 4)
- EVP, Chief Scientific Ofc, COO Wassil Jim exercised 2,250 shares at a strike of $5.35 and sold $137,024 worth of shares (2,250 units at $60.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Vaxcyte Inc.
- Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
- SEC Form 8-K filed by Vaxcyte Inc.
- Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes